Clareo Health | A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants
Adult subjects with a histologically or cytologically confirmed diagnosis of Stage IIIB, IIIC, or IV sqNSCLC that is not amenable to curative treatment
At least one lesion with measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by the local site investigator/radiology assessment.
Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Adequate hematological, renal, hepatic, and coagulation function.
Females of childbearing potential must have a negative pregnancy test
You may not be if
Prior systemic treatment received for locally advanced or metastatic NSCLC.
Histologically or cytologically confirmed non-sqNSCLC.
Known actionable genomic alterations (including EGFR, ALK, ROS1, BRAF, NTRK, RET, and MET) for which first-line approved therapies are available.
Active central nervous system (CNS) metastases and/or carcinomatous meningitis.
